WESTFORD, Mass., May 7 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that it has received market approval from the Korea Food & Drug Administration (KFDA) for its flagship Accolade(TM) workstation for the removal of pigmented lesions.
Introduced in the first quarter of 2008, the Accolade is the third Cynosure flagship product approved for marketing in South Korea, following the Elite(TM) Aesthetic Workstation for laser hair removal and the Cynergy(TM) Workstation with MultiPlex(TM) Technology for the treatment of dermatological vascular conditions. All three workstations are being distributed in South Korea through Seoul-based OrientMG Ltd.
"As one of the world's major aesthetic markets, we believe South Korea represents a valuable growth opportunity for our products, and we are excited about the receipt of KFDA approval for our newest flagship product," said Cynosure President and Chief Executive Officer Michael Davin. "Due to the prevalence of dermal melanoses among Asian populations, South Korea is a primary target market for Accolade. We also are pursuing regulatory approval in other Asia Pacific countries, including China."
Accolade is a high-powered 755 nm, Q-switched Alexandrite laser for the removal of pigmented lesions. The unique combination of various spot sizes and the laser's high repetition rates allow for rapid treatment.
"With its power and precision, Accolade is well-suited for treating the full spectrum of benign pigmented lesions including Nevus of Ota, solar lentigenes, freckles and sun-damaged pigmentation," said Dr. Joon-hong Park of the Maymorning Clinic in Sungnam City, Kyunggi-Do, South Korea. "The accuracy of the aiming beam makes the Accolade easy to handle- treatment is delivered with specificity, minimizing side effects to the surrounding tissue and maximizing patient comfort."
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.
Any statements in this press release about future expectations, plans
and prospects for Cynosure, Inc., including statements about the company's
expectations and future financial performance, as well as other statements
containing the words "believes," "anticipates," "plans," "expects," "will"
and similar expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including Cynosure's
reliance on sole source suppliers, the inability to accurately predict the
timing or outcome of regulatory decisions, changes in consumer preferences,
competition in the aesthetic laser industry, economic, market,
technological and other factors discussed in Cynosure's most recent Annual
Report on Form 10-K, which is filed with the Securities and Exchange
Commission. In addition, the forward-looking statements included in this
press release represent Cynosure's views as of the date of this press
release. Cynosure anticipates that subsequent events and developments will
cause its views to change. However, while Cynosure may elect to update
these forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Cynosure's views as of
any date subsequent to the date of this press release.
Sharon Merrill Associates, Inc.
|SOURCE Cynosure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved